Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
Key Highlights
- ➤Stryker (SYK) will invest approximately $400 million in CMR Surgical preferred equity
- ➤Stryker receives an exclusive option to acquire 100% of CMR Surgical
- ➤Stryker becomes exclusive U.S. sales agent for the Versius portfolio
- ➤CMR Surgical will lead Versius development and non-U.S. commercialization
- ➤Transaction requires regulatory approvals and customary closing conditions
Expert Statements
Andy Pierce, Group President, Medsurg and Neurotechnology, Stryker
“Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker’s strengths in endoscopy, visualization and enabling technologies. We have evaluated the segment carefully for years, and this alliance represents a thoughtful and disciplined entry that combines the complementary strengths of both companies.”
Andy Pierce, Group President, Medsurg and Neurotechnology, Stryker
“We selected CMR Surgical and the Versius portfolio because of the opportunity to help healthcare providers grow robotic-assisted surgery adoption across a broad range of procedures in hospitals and ASCs.”
Massimiliano Colella, Chief Executive Officer of CMR Surgical
“This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built.”
Massimiliano Colella, Chief Executive Officer of CMR Surgical
“Stryker’s investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio, while its scale and deep customer relationships create a significant growth opportunity in the United States.”
Massimiliano Colella, Chief Executive Officer of CMR Surgical
“We also look forward to welcoming Andy Pierce to our board of directors and benefiting from his more than 30 years of MedTech leadership experience at Stryker as we continue expanding access to robotic-assisted surgery globally.”
Portage, Mich., USA and Cambridge, England, Oct. 12, 2026 (GLOBE NEWSWIRE) --
Strategic alliance combines CMR Surgical’s established platform and robotics expertise with Stryker’s scale, customer relationships and commercial reach to accelerate growth of the Versius Surgical Robotic portfolio * Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical to support future innovation and global commercialization of the Versius portfolio, subject to customary closing conditions * The preferred equity investment also grants Stryker an exclusive option to acquire 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement's terms * Stryker will serve as the exclusive U.S. sales agent for the Versius portfolio Stryker (NYSE:SYK), a global leader in medical technologies, and CMR Surgical, a global robotics company, today announced a strategic equity investment of approximately $400 million (£300 million) by Stryker with an exclusive option for Stryker to acquire the remaining equity of CMR Surgical, and an exclusive U.S. commercial agency agreement for the Versius portfolio.
Get started
Create a free account to read the full story.